GST 2.0 will make cancer treatment cheaper: Life-saving drugs for cancer and chronic diseases exempted from GST

The rollout of GST 2.0 from 22 September 2025 marks a major relief for patients battling cancer and other chronic illnesses in India. Under the revised GST regime, 33 life-saving drugs and medicines have been exempted from GST, while three critical drugs used for cancer, rare diseases, and severe chronic conditions are also taxed at zero percent. In addition, most other medicines will see a reduced GST rate from 12% to 5%. The reform extends to medical devices, diagnostic kits, and individual health and life insurance policies, reducing costs significantly and making healthcare more affordable and accessible for millions of households nationwide.The GST Council has made specific revisions to lower the financial burden of healthcare:These changes are expected to make medicines, treatments, and healthcare services significantly more affordable for patients across India.The GST exemptions directly reduce out-of-pocket expenses for patients undergoing treatment for serious illnesses. Cancer patients, in particular, will benefit from lower prices on therapies involving life-saving drugs. Similarly, those suffering from rare genetic disorders or chronic conditions requiring specialty medications will see considerable financial relief. Early diagnosis, adherence to treatment schedules, and ongoing care become more manageable, improving patient outcomes and access to advanced therapies.Beyond medicines, the GST 2.0 reforms cover essential medical devices and supplies:The GST revisions will come into effect from 22 September 2025, coinciding with the broader GST 2.0 rollout. Patients, hospitals, pharmacies, and insurance providers can now benefit from reduced taxes on critical medicines, devices, and policies, making India’s healthcare system more patient-friendly and cost-effective. These reforms are being hailed as a landmark step in India’s healthcare policy. Experts believe GST 2.0 could set a precedent for other countries seeking to lower medical costs.